Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients

Vañó‐Galván, Sergio; Pirmez, Rodrigo; Hermosa-Gelbard, Ángela; Moreno‐Arrones, Óscar M.; Saceda‐Corralo, David; Rodrigues‐Barata, Rita; ­Jimenez‐Cauhe, Juan; Koh, Wei Liang; Poa, Janina Eliza; Jerjen, Rebekka; Carvalho, Lara Trindade de; John, Jared Marc; Salas‐Callo, Corina Isabel; Vincenzi, Colombina; Yin, Lu; LoSicco, Kristen; Waśkiel‐Burnat, Anna; Starace, Michela; Zamorano, José Luís; Jaén‐Olasolo, Pedro; Piraccini, Bianca Maria; Rudnicka, Lidia; Shapiro, Jerry; Tosti, Antonella; Sinclair, Rodney; Bhoyrul, Bevin

doi:10.1016/j.jaad.2021.02.054

Cited by 90 publications

(112 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there was no significant difference in hair density, there was a trend towards greater improvement in the oral group. Further data from a large multicentre study have demonstrated its efficacy and safety in AGA 79 .…”

Section: Therapeuticsmentioning

confidence: 95%

Advances in hair growth

Wall¹,

Meah²,

Fagan³

et al. 2022

Fac Rev

Self Cite

View full text Add to dashboard Cite

Hair is a deeply rooted component of identity and culture. Recent articles in this series have focused on scientific evidence relating to hair growth and new insights into the pathogenesis and mechanism of hair loss. This article reviews emerging evidence that has advanced our understanding of hair growth in both of these areas to provide a context for outlining current and emerging therapies. These include finasteride, minoxidil, topical prostaglandins, natural supplements, microneedling, low-level laser light, platelet-rich plasma, fractional lasers, cellular therapy, Wnt activators and SFRP1 antagonism.

show abstract

Section: Therapeuticsmentioning

confidence: 95%

Advances in hair growth

Wall¹,

Meah²,

Fagan³

et al. 2022

Fac Rev

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although it may be more convenient for patients to take the oral form of minoxidil, its systemic side effects such as increased heart rate, weight gain, hirsutism, hypertrichosis, and lower extremity edema make it unfavorable compared to topical minoxidil as a first‐line treatment 22 . In a recent study of 1404 subjects, the most common side effect was noted to be hypertrichosis in about 15% of patients and the incidence of systemic adverse effects was noted in 1.7% of patients 81 . Oral minoxidil's side effects, however, are typically dose‐dependent and reversible with discontinuation of the drug.…”

Section: Oral Therapiesmentioning

confidence: 99%

Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics

Nestor

Ablon

Gade

et al. 2021

J of Cosmetic Dermatology

153

105

View full text Add to dashboard Cite

show abstract

“…Oral minoxidil 5 mg daily is a therapeutic option for male patients with androgenetic alopecia The safety and efficacy of oral minoxidil at low dose for the treatment of androgenetic alopecia have been evaluated in recent studies. 2,3,7,27,28 Although experts agreed on the recommendation, several concerns were raised during the meeting, like the fact that low doses are not commercially available in most countries and the drug needs to be compounded in the pharmacy. Oral minoxidil is used for the treatment of hypertension, so any alteration in the compounding could lead to cardiovascular complications.…”

Section: Non-cicatricial Alopeciamentioning

confidence: 99%

“…New advances in trichology have proposed low-dose oral minoxidil, [2][3][4][5][6][7] bicalutamide, 8-10 dustasteride 11 and platelet-rich plasma (PRP) 12,13 for the treatment of different types of alopecia. Besides drug treatments, hair transplantation (HT) has also emerged as a therapeutic option for many patients with noncicatricial alopecia, but its effectiveness in cicatricial alopecia remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

Current controversies in trichology: a European expert consensus statement

Meyer-Gonzalez¹,

Bacqueville

Grimalt

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Introduction Hair disorders are one of the most common conditions within dermatology practice but, although new diagnostic tools and therapeutic options have arisen, the management of these patients still represents a major clinical challenge. ObjectiveThis study aimed at gathering information and achieving consensus on relevant recommendations on the latest advances in alopecia, trichoscopy and hair dermocosmetics.Methods Experts of the steering committee consulted the available evidence on trichology-related areas from the past 5 years and formulated recommendations based on the evidence and their experience. A modified two-round Delphi procedure was performed among 45 European dermatologists experts in trichology to consult their degree of agreement on twenty recommendations, using a 4-point Likert scale. Consensus was defined as >80% of participants scoring either 1 (totally agree) or 2 (agree). ResultsIn the first round of the Delphi questionnaire, 75% of the recommendations reached consensus. Those that were not agreed upon were reformulated by the steering committee and voted again after an online meeting, where consensus was achieved in all recommendations.Conclusions All recommendations reached consensus after the two-round Delphi questionnaire and may be useful in clinical practice for dermatologists. The participants agreed that besides this consensus, further clinical studies are needed to assess the benefits of the emerging tools and treatments and to clarify the controversies that still exist in the field, aiming at improving patients' quality of life.

show abstract

Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients

Cited by 90 publications

References 26 publications

Advances in hair growth

Advances in hair growth

Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics

Current controversies in trichology: a European expert consensus statement

Contact Info

Product

Resources

About